Novel resveratrol and 5-fluorouracil coencapsulated in PEGylated nanoliposomes improve chemotherapeutic efficacy of combination against head and neck squamous cell carcinoma

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Mohan, Aarti ^a   Narayanan, Shridhar ^b   Sethuraman, Swaminathan ^a   Krishnan, Uma Maheswari ^a  

^a SASTRA UNIVERSITY   (India)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; GLYCEROL; LIPOSOME; NANOCARRIER; PHOSPHATE; PLANT MEDICINAL PRODUCT; RESVERATROL; RESVERATROL PLUS 5 FLUOROURACIL; UNCLASSIFIED DRUG; MACROGOL DERIVATIVE; NANOPARTICLE; STILBENE DERIVATIVE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG RELEASE; GENE EXPRESSION PROFILING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; IN VITRO STUDY; LIPID MEMBRANE; NANOENCAPSULATION; NUCLEAR MAGNETIC RESONANCE; SQUAMOUS CELL CARCINOMA CELL LINE; THERMAL ANALYSIS; CELL PROLIFERATION; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HEAD AND NECK TUMOR; HUMAN; METABOLISM; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; LIPOSOMES; NANOPARTICLES; POLYETHYLENE GLYCOLS; STILBENES;

EID: 84904791733     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/424239     Document Type: Article

References (58)

1. Holoye P. Y., Byers R. M., Gard D. A., Goepfert H., Guillamondegui O. M., Jesse R. H., Combination chemotherapy of head and neck cancer. Cancer 1978 42 4 1661 1669 10.1002/1097-0142(197810)42:4<1661::AID-CNCR2820420402>3.0. CO;2-F 2-s2.0-0018129269 (Pubitemid 9053503)
2. Bernier J., Domenge C., Ozsahin M., Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. The New England Journal of Medicine 2004 350 1945 1952 (Pubitemid 38580197)
3. Keil F., Selzer E., Berghold A., Reinisch S., Kapp K. S., De Vries A., Greil R., Bachtiary B., Tinchon C., Anderhuber W., Burian M., Kasparek A., Elsäßer W., Kainz H., Riedl R., Kopp M., Kornek G., Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck. European Journal of Cancer 2013 49 2 352 359 10.1016/j.ejca.2012. 08.004 2-s2.0-84872114190
4. Lorch J. H., Goloubeva O., Haddad R. I., Cullen K., Sarlis N., Tishler R., Tan M., Fasciano J., Sammartino D. E., Posner M. R., Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. The Lancet Oncology 2011 12 2 153 159 10.1016/S1470-2045(10)70279-5 2-s2.0-79151485327
5. Rütten H., Pop L. A. M., Janssens G. O. R. J., Takes R. P., Knuijt S., Rooijakkers A. F., Van Den Berg M., Merkx M. A., Van Herpen C. M. L., Kaanders J. H. A. M., Long-term outcome and morbidity after treatment with accelerated radiotherapy and weekly cisplatin for locally advanced head-and-neck cancer: results of a multidisciplinary late morbidity clinic. International Journal of Radiation Oncology, Biology, Physics 2011 81 4 923 929 10.1016/j.ijrobp.2010.07.013 2-s2.0-80255135522
6. Merlano M., Russi E., Benasso M., Corvò R., Colantonio I., Vigna-Taglianti R., Vigo V., Bacigalupo A., Numico G., Crosetto N., Gasco M., Lo Nigro C., Vitiello R., Violante S., Garrone O., Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study. Annals of Oncology 2011 22 3 712 717 10.1093/annonc/mdq412 2-s2.0-79952012758
7. Allen T. M., Cullis P. R., Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews 2013 65 1 36 48 10.1016/j.addr.2012.09.037 2-s2.0-84873252557
8. Chang H. I., Yeh M. K., Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. International Journal of Nanomedicine 2012 7 49 60 2-s2.0-84856638259
9. Barenholz Y., Doxil: the first FDA-approved nano-drug: lessons learned. Journal of Controlled Release 2012 160 2 117 134 10.1016/j.jconrel.2012.03.020 2-s2.0-84861669644
10. Stathopoulos G. P., Liposomal cisplatin: a new cisplatin formulation. Anti-Cancer Drugs 2010 21 8 732 736 10.1097/CAD.0b013e32833d9adf 2-s2.0-77955194093
11. Boulikas T., Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin. Expert Opinion on Investigational Drugs 2009 18 8 1197 1218 10.1517/13543780903114168 2-s2.0-68049142557
12. 2) in the treatment of gynecologic cancers. Gynecologic Oncology 2005 97 2 374 378 10.1016/j.ygyno.2004.12.057 2-s2.0-18144392975 (Pubitemid 40614877)
13. Slingerland M., Guchelaar H., Gelderblom H., Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discovery Today 2012 17 3-4 160 166 10.1016/j.drudis.2011.09.015 2-s2.0-84856452267
14. Shankar S., Singh B. N., Srivastava R. K., Shankar S., Srivastava R. K., Plant polyphenols and their role in cancer prevention and chemotherapy. Nutrition, Diet and Cancer 2012 Berlin, Germany Springer 209 234 10.1007/978-94-007-2923-0-10
15. Korkina L. G., Pastore S., Dellambra E., de Luca C., New molecular and cellular targets for chemoprevention and treatment of skin tumors by plant polyphenols: a critical review. Current Medicinal Chemistry 2013 20 7 852 868 2-s2.0-84877995487
16. + exchange as a mechanism of rapid cardioprotection by resveratrol. British Journal of Pharmacology 2012 166 6 1745 1755 10.1111/j.1476-5381.2012.01877.x 2-s2.0-84863207184
17. Li H., Xia N., Förstermann U., Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide 2012 26 2 102 110 10.1016/j.niox.2011.12. 006 2-s2.0-84862777886
18. Tsai Y., Liu F., Lau Y., Yu H., Role of Akt-dependent pathway in resveratrol-mediated cardioprotection after trauma-hemorrhage. Journal of Surgical Research 2012 176 1 171 177 10.1016/j.jss.2011.05.039 2-s2.0-84860825929
19. Wang S., Bo Q., Zhao X., Yang X., Chi Z., Liu X., Resveratrol pre-treatment reduces early inflammatory responses induced by status epilepticus via mTOR signaling. Brain Research 2013 1492 122 129 10.1016/j.brainres.2012. 11.027 2-s2.0-84871919060
20. Nessa M. U., Beale P., Chan C., Yu J. Q., Huq F., Combinations of resveratrol, cisplatin and oxaliplatin applied to human ovarian cancer cells. Anticancer Research 2012 32 1 53 59 2-s2.0-84862960768
21. Erdem T., Bayindir T., Filiz A., Iraz M., Selimoglu E., The effect of resveratrol on the prevention of cisplatin ototoxicity. European Archives of Oto-Rhino-Laryngology 2012 269 10 2185 2188 10.1007/s00405-011-1883-5 2-s2.0-84867242436
22. Dudka J., Gieroba R., Korga A., Burdan F., Matysiak W., Jodlowska-Jedrych B., Mandziuk S., Korobowicz E., Murias M., Different effects of resveratrol on dose-related doxorubicin-induced heart and liver toxicity. Evidence-Based Complementary and Alternative Medicine 2012 2012 10 606183 10.1155/2012/606183 2-s2.0-84871367719
23. Scott E., Steward W. P., Gescher A. J., Brown K., Resveratrol in human cancer chemoprevention-choosing the "right" dose. Molecular Nutrition and Food Research 2012 56 1 7 13 10.1002/mnfr.201100400 2-s2.0-84855334376
24. Tome-Carneiro J., Larrosa M., Gonzalez-Sarrias A., Tomas-Barberan F. A., Garcia-Conesa M. T., Espin J. C., Resveratrol and clinical trials: the crossroads from in vitro studies to human evidence. Current Pharmaceutical Design 2013 19 6064 6093
25. Chan J. Y., Meng S. P., Clement M. V., Pervaiz S., Shao C. L., Resveratrol displays converse dose-related effects on 5-fluorouracilevoked colon cancer cell apoptosis: the roles of caspase-6 and p53. Cancer Biology and Therapy 2008 7 8 1305 1312 10.4161/cbt.7.8.6302 2-s2.0-49749128400
26. Mohapatra P., Preet R., Choudhuri M., Choudhuri T., Kundu C. N., 5-Fluorouracil increases the chemopreventive potentials of resveratrol through DNA damage and MAPK signaling pathway in human colorectal cancer cells. Oncology Research 2011 19 7 311 321 10.3727/096504011X13079697132844 2-s2.0-80051879888
27. Wu S. L., Sun Z. J., Yu L., Meng K. W., Qin X. L., Pan C. E., Effect of resveratrol and in combination with 5-FU on murine liver cancer. World Journal of Gastroenterology 2004 10 20 3048 3052 2-s2.0-4644323714 (Pubitemid 39303061)
28. Singh M., Bhatnagar P., Srivastava A. K., Kumar P., Shukla Y., Gupta K. C., Enhancement of cancer chemosensitization potential of cisplatin by tea polyphenols poly(lactide-co-glycolide) nanoparticles. Journal of Biomedical Nanotechnology 2011 7 1, article 202 10.1166/jbn.2011.1268 2-s2.0-79957695361
29. Wong M., Chiu G. N. C., Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab- insensitive breast tumor xenograft model. Nanomedicine 2011 7 6 834 840 10.1016/j.nano.2011.02.001 2-s2.0-82255193872
30. Mulherkar R., Goud A. P., Wagle A. S., Naresh K. N., Mahimkar M. B., Thomas S. M., Pradhan S. A., Deo M. G., Establishment of a human squamous cell carcinoma cell line of the upper aero-digestive tract. Cancer Letters 1997 118 1 115 121 10.1016/S0304-3835(97)00241-3 2-s2.0-0030825792 (Pubitemid 27397232)
31. Mashru R. C., Sutariya V. B., Sankalia M. G., Parikh P. P., Development and evaluation of fast-dissolving film of salbutamol suplhate. Drug Development and Industrial Pharmacy 2005 31 1 25 34 10.1081/DDC-43947 2-s2.0-12844273561 (Pubitemid 40170585)
32. Gohel M. C., Parikh R. K., Aghara P. Y., Nagori S. A., Delvadia R. R., Dabhi M. R., Application of simplex lattice design and desirability function for the formulation development of mouth dissolving film of salbutamol sulphate. Current Drug Delivery 2009 6 5 486 494 10.2174/156720109789941696 2-s2.0-72149103254
33. Voigt W., Methods Molecular Medicine 2005 110 New York, NY, USA Springer edited by R. D. Blumenthal
34. Chou T. C., Theoretical basis, experimental design and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological Reviews 2006 58 3 621 681 10.1124/pr.58.3.10 (Pubitemid 44403686)
35. Immordino M. L., Dosio F., Cattel L., Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. International Journal of Nanomedicine 2006 1 3 297 315 10.2217/17435889.1.3.297 2-s2.0-34548482374
36. Maruyama K., Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Advanced Drug Delivery Reviews 2011 63 3 161 169 10.1016/j.addr.2010.09.003 2-s2.0-79953053224
37. Maruyama K., Yuda T., Okamoto A., Kojima S., Suginaka A., Iwatsuru M., Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). Biochimica et Biophysica Acta 1992 1128 1 44 49 10.1016/0005-2760(92)90255-T 2-s2.0-0026671099
38. Mac Lachlan I., Crooke S. T., Liposomal formulations for nucleic acid delivery. Antisense Drug Technology: Principles, Strategies and Applications 2008 9 Boca Raton, Fla, USA CRC Press
39. Demetzos C., Differential Scanning Calorimetry (DSC): a tool to study the thermal behavior of lipid bilayers and liposomal stability. Journal of Liposome Research 2008 18 3 159 173 10.1080/08982100802310261 2-s2.0-51149111419
40. Fabris S., Momo F., Ravagnan G., Stevanato R., Antioxidant properties of resveratrol and piceid on lipid peroxidation in micelles and monolamellar liposomes. Biophysical Chemistry 2008 135 1-3 76 83 10.1016/j.bpc.2008.03.005 2-s2.0-43049146486
41. Sarpietro M. G., Spatafora C., Tringali C., Micieli D., Castelli F., Interaction of resveratrol and its trimethyl and triacetyl derivatives with biomembrane models studied by differential scanning calorimetry. Journal of Agricultural and Food Chemistry 2007 55 9 3720 3728 10.1021/jf070070q 2-s2.0-34249277449 (Pubitemid 46806598)
42. Wesołowska O., Kuzdzał M., Štrancar J., Michalak K., Interaction of the chemopreventive agent resveratrol and its metabolite, piceatannol, with model membranes. Biochimica et Biophysica Acta: Biomembranes 2009 1788 9 1851 1860 10.1016/j.bbamem.2009.06.005 2-s2.0-68749120811
43. Brittes J., Lúcio M., Nunes C., Lima J. L. F. C., Reis S., Effects of resveratrol on membrane biophysical properties: relevance for its pharmacological effects. Chemistry and Physics of Lipids 2010 163 8 747 754 10.1016/j.chemphyslip.2010.07.004 2-s2.0-78049475228
44. Selvaraj S., Mohan A., Narayanan S., Sethuraman S., Krishnan U. M., Dose-dependent interaction of trans-resveratrol with biomembranes: effects on antioxidant property. Journal of Medicinal Chemistry 2013 56 3 970 981 10.1021/jm3014579 2-s2.0-84873921497
45. Auger M., Biological membrane structure by solid-state NMR. Current issues in molecular biology 2000 2 4 119 124 2-s2.0-0034303792
46. 31P solid-state NMR study. Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids 2004 1682 1-3 28 37 10.1016/j.bbalip.2004.01.004 2-s2.0-2442651203 (Pubitemid 38670532)
47. El Maghraby G. M. M., Williams A. C., Barry B. W., Drug interaction and location in liposomes: correlation with polar surface areas. International Journal of Pharmaceutics 2005 292 1-2 179 185 10.1016/j.ijpharm.2004.11.037 2-s2.0-13844297709 (Pubitemid 40255799)
48. Okamura E., Yoshii N., Drug binding and mobility relating to the thermal fluctuation in fluid lipid membranes. The Journal of Chemical Physics 2008 129 21 215102 10.1063/1.3023035 2-s2.0-57349196760
49. Georgiev G. A., Sarker D. K., Al-Hanbali O., Georgiev G. D., Lalchev Z., Effects of poly (ethylene glycol) chains conformational transition on the properties of mixed DMPC/DMPE-PEG thin liquid films and monolayers. Colloids and Surfaces B: Biointerfaces 2007 59 2 184 193 10.1016/j.colsurfb.2007.05.006 2-s2.0-34547660293 (Pubitemid 47211787)
50. Sabín J., Prieto G., Ruso J. M., Hidalgo-Álvarez R., Sarmiento F., Size and stability of liposomes: a possible role of hydration and osmotic forces. The European Physical Journal E 2006 20 4 401 408 10.1140/epje/i2006-10029-9 2-s2.0-33748638825 (Pubitemid 44386800)
51. Garcia-Manyes S., Oncins G., Sanz F., Effect of ion-binding and chemical phospholipid structure on the nanomechanics of lipid bilayers studied by force spectroscopy. Biophysical Journal 2005 89 3 1812 1826 10.1529/biophysj.105. 064030 2-s2.0-24144502022 (Pubitemid 41233536)
52. Cserháti T., Szögyi M., Interaction between phospholipids and monovalent cations studied by a new thin-layer chromatographic method. Chemistry and Physics of Lipids 1983 34 1 93 99 10.1016/0009-3084(83)90062-2 2-s2.0-0021008289
53. Costa P., Sousa Lobo J. M., Modeling and comparison of dissolution profiles. European Journal of Pharmaceutical Sciences 2001 13 2 123 133 10.1016/S0928-0987(01)00095-1 2-s2.0-0035073301 (Pubitemid 32288781)
54. Glavas-Dodov M., Fredro-Kumbaradzi E., Goracinova K., Calis S., Simonoska M., Hincal A. A., 5-Fluorouracil in topical liposome gels for anticancer treatment-formulation and evaluation. Acta Pharmaceutica 2003 53 4 241 250 2-s2.0-0345827819 (Pubitemid 38083939)
55. Chou T., Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Research 2010 70 2 440 446 10.1158/0008-5472. CAN-09-1947 2-s2.0-76549129820
56. Chou T., Talalay P., Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation 1984 22 27 55 10.1016/0065-2571(84)90007-4 2-s2.0-0021118703
57. Chou T. C., Assessment of synergistic and antagonistic effects of chemotherapeutic agents in vitro. Contributions to Gynecology and Obstetrics 1994 19 91 107 2-s2.0-0028723934
58. Tallarida R. J., Revisiting the isobole and related quantitative methods for assessing drug synergism. Journal of Pharmacology and Experimental Therapeutics 2012 342 1 2 8 10.1124/jpet.112.193474 2-s2.0-84862488682